This HTML5 document contains 71 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/mesh/concept/
n5http://linked.opendata.cz/resource/drugbank/company/
n6http://linked.opendata.cz/resource/drugbank/dosage/
n19http://linked.opendata.cz/resource/drugbank/mixture/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00815/identifier/chebi/
n18http://bio2rdf.org/drugbank:
n10http://linked.opendata.cz/resource/drugbank/drug/DB00815/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n15http://linked.opendata.cz/resource/drugbank/drug/DB00815/identifier/pharmgkb/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00815/identifier/kegg-compound/
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n11http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00815/identifier/kegg-drug/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/drugbank/drug/DB00815/identifier/drugbank/

Statements

Subject Item
n2:DB00815
rdf:type
n3:Drug
n3:description
Sodium Lauryl Sulfate (SLS) is an anionic surfactant naturally derived from coconut and/or palm kernel oil. It usually consisting of a mixture of sodium alkyl sulfates, mainly the lauryl. SLS lowers surface tension of aqueous solutions and is used as fat emulsifier, wetting agent, and detergent in cosmetics, pharmaceuticals and toothpastes. It is also used in creams and pastes to properly disperse the ingredients and as research tool in protein biochemistry. SLS also has some microbicidal activity.
n3:dosage
n6:271B42D7-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Agner T: Susceptibility of atopic dermatitis patients to irritant dermatitis caused by sodium lauryl sulphate. Acta Derm Venereol. 1991;71(4):296-300. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1681644 # Marrakchi S, Maibach HI: Sodium lauryl sulfate-induced irritation in the human face: regional and age-related differences. Skin Pharmacol Physiol. 2006;19(3):177-80. Epub 2006 May 4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16679819 # Loffler H, Effendy I: Skin susceptibility of atopic individuals. Contact Dermatitis. 1999 May;40(5):239-42. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10344477 # Chahine L, Sempson N, Wagoner C: The effect of sodium lauryl sulfate on recurrent aphthous ulcers: a clinical study. Compend Contin Educ Dent. 1997 Dec;18(12):1238-40. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9656847 # Herlofson BB, Barkvoll P: The effect of two toothpaste detergents on the frequency of recurrent aphthous ulcers. Acta Odontol Scand. 1996 Jun;54(3):150-3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8811135 # Piret J, Desormeaux A, Bergeron MG: Sodium lauryl sulfate, a microbicide effective against enveloped and nonenveloped viruses. Curr Drug Targets. 2002 Feb;3(1):17-30. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11899262
n3:group
approved
n3:indication
SLS is used as a surfactant in shampoos and toothpastes. SLS also has microbicidal activities against both enveloped (Herpes simplex viruses, HIV-1, Semliki Forest virus) and nonenveloped (papillomaviruses, reovirus, rotavirus and poliovirus) viruses, although it has not been approved for this use.
owl:sameAs
n8:DB00815 n18:DB00815
dcterms:title
Sodium lauryl sulfate
adms:identifier
n10:Sodium_lauryl_sulfate n13:8984 n14:D01045 n15:PA451398 n16:DB00815 n17:C11166
n3:mechanismOfAction
Like other surfactants, SLS is amphiphilic. It thus migrates to the surface of liquids, where its alignment and aggregation with other SLS molecules lowers the surface tension. This allows for easier spreading and mixing of the liquid. SLS has potent protein denaturing activity and inhibits the infectivity of viruses by by solubilizing the viral envelope and/or by denaturing envelope and/or capsid proteins.
n3:packager
n5:271B42D2-363D-11E5-9242-09173F13E4C5 n5:271B42D3-363D-11E5-9242-09173F13E4C5 n5:271B42D0-363D-11E5-9242-09173F13E4C5 n5:271B42D1-363D-11E5-9242-09173F13E4C5
n3:synonym
Sodium dodecylsulfate SLS SDS Sodium laurilsulfate Sodium dodecyl sulfate Sodium lauryl sulfate Laurylsiran sodny Sodium lauryl sulphate Sodium dodecyl sulphate NaDS Natrium laurylsulfuricum
n3:toxicity
Oral (LD50): Acute: 1288 mg/kg [Rat]
n3:mixture
n19:271B42CD-363D-11E5-9242-09173F13E4C5 n19:271B42CE-363D-11E5-9242-09173F13E4C5 n19:271B42CF-363D-11E5-9242-09173F13E4C5
n3:synthesisReference
Willi Breitzke, Hermann Hensen, "Aqueous preparations of sodium lauryl sulfate and myristyl sulfate having a low cloud point useful in making toothpastes." U.S. Patent US4876035, issued June, 1960.
n11:hasConcept
n12:M0020097
n3:IUPAC-Name
n4:271B42DC-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B42E2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B42E1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B42DE-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B42DF-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B42E0-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B42DA-363D-11E5-9242-09173F13E4C5 n4:271B42F1-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B42F3-363D-11E5-9242-09173F13E4C5 n4:271B42DB-363D-11E5-9242-09173F13E4C5 n4:271B42D8-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B42D9-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B42E8-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B42E9-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B42E3-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B42E4-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B42E6-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B42E5-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B42E7-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
151-21-3
n3:category
n3:containedIn
n20:271B42D5-363D-11E5-9242-09173F13E4C5 n20:271B42D6-363D-11E5-9242-09173F13E4C5 n20:271B42D4-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B42ED-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B42EF-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B42F0-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B42F2-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B42EC-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B42EB-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B42EE-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B42DD-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B42EA-363D-11E5-9242-09173F13E4C5